About
An independent read on U.S. market access.
We built the diagnostic we wanted to use ourselves: the tests first, the thresholds in the open, and the honest answer about which routes are open to a company your size.
The desk
Canadian issuers are usually told what a U.S. listing costs before anyone checks whether they qualify. The order matters: float, foreign private issuer status, reporting history and the exchange price tests decide which door is open, and most of that is knowable in four minutes.
The platform
Rules in the open, not a black box.
Every threshold on this site shows where it comes from and when it was last verified.
What this platform does
The diagnostic runs the eligibility tests that decide whether a Canadian issuer can reach U.S. capital under the Multijurisdictional Disclosure System: Canadian incorporation, a foreign private issuer profile, at least twelve months of continuous Canadian reporting, and US$75 million of non-affiliate public float measured within sixty days of filing. It scores each path — Form F-10 and Form 40-F, the Form F-7 rights offering, and the F-8 and F-80 business combination forms — and shows which input drives each conclusion.
Beyond eligibility it models the practical questions: the public float arithmetic with only holders above ten per cent deducted, the foreign private issuer retest, a readiness score across filing, audit, governance and market depth, and a reverse-split versus ADR model for reaching the US$4.00 initial listing price. Every threshold carries its source type and a last-verified date, and the rules are versioned so a conclusion can be reproduced later. You can export the whole assessment as a PDF, read the learning centre, or put a question to the desk.
Who it is for
Canadian issuers already listed on the TSX, TSXV or CSE, and the chief executives, finance leads, boards and investor relations teams who have to decide whether a U.S. listing, an OTCQX quotation or a first registered offering is worth the cost. It is built for companies testing a decision before commissioning a memorandum, and for the counsel, auditors and advisors who want an independent second read on where a client actually stands.
Ari Gross, Founder
Ari Gross is a Toronto-based capital markets adviser with a background in special-situations investing and small-cap shareholder activism. He worked as an operations analyst at Bryant Street Capital Management, a special-situations equity fund, before founding Capital AnG and Ventures of Space.
His current advisory work includes a Canadian biotech company pursuing a Nasdaq uplisting, a medtech IPO, and a robotics spinout targeting a U.S. listing. He also advises companies on bridge financing, convertible debt, and growth capital, and brings relationships with family offices, hedge funds and investment banks across Canada and the U.S.
He works directly with Canadian issuers on U.S. market access: eligibility and float modelling first, then the registration route, the disclosure package, and the coordination with Canadian and U.S. counsel, auditors, filing agents and banking partners that carries a filing to completion.
Every submission through this site is read by him, and every first call is with him. If the honest answer is that the timing does not work yet, that is the answer you get.
How the rules are maintained
The desk works between Toronto and New York, coordinating with U.S. and Canadian counsel, PCAOB-registered auditors and exchange contacts on eligibility, structure, documentation and execution. The rule set behind the diagnostic is maintained there and reviewed against Canadian securities rules and U.S. exchange listing standards, and every threshold shows its source and the date it was last checked.
MJDS Advisory is not a law firm, dealer or investment adviser, and it does not sell securities. Nothing here is legal, tax or investment advice, and final determinations require review by qualified counsel and by the relevant exchange or regulator.